Literature DB >> 10683850

Histamine H3-receptor activation inhibits dopamine synthesis in rat striatum.

A Molina-Hernández1, A Nuñez, J A Arias-Montaño.   

Abstract

Unilateral 6-hydroxydopamine lesion to rat substantia nigra pars compacta resulted in a modest, but significant, decrease in the specific binding of N-alpha-[methyl-3H]histamine (19 +/- 5% reduction) to synaptosomal membranes from ipsilateral striata. Dopamine synthesis was assessed in striatal slices by determining [3H]DOPA accumulation after inhibition of DOPA decarboxylase. [3H]DOPA synthesis induced by 50 mM K+ (151 +/- 4% of basal) was prevented by either Ca2+ removal or by Ni2+. Depolarization-stimulated [3H]DOPA accumulation was reduced by the selective H3-agonist immepip (100 nM; 68 +/- 7% inhibition). The effect of immepip was reversed by thioperamide (100 nM), a selective H3-antagonist. Taken together, our results indicate that histamine modulates striatal dopamine synthesis by acting at H3-receptors located on dopaminergic nerve terminals.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683850     DOI: 10.1097/00001756-200001170-00032

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  17 in total

1.  Histamine H(3) receptor-mediated inhibition of depolarization-induced, dopamine D(1) receptor-dependent release of [(3)H]-gamma-aminobutryic acid from rat striatal slices.

Authors:  J A Arias-Montaño; B Floran; M Garcia; J Aceves; J M Young
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function.

Authors:  Carla Ferrada; Sergi Ferré; Vicent Casadó; Antonio Cortés; Zuzana Justinova; Chanel Barnes; Enric I Canela; Steven R Goldberg; Rob Leurs; Carme Lluis; Rafael Franco
Journal:  Neuropharmacology       Date:  2008-05-16       Impact factor: 5.250

3.  New insights into the organization of the basal ganglia.

Authors:  James B Koprich; Tom H Johnston; Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Curr Neurol Neurosci Rep       Date:  2009-07       Impact factor: 5.081

Review 4.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

Review 5.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

6.  Thioperamide, an H₃ receptor antagonist prevents [³H]glucose uptake in brain of adult rats lesioned as neonates with 5,7-dihydroxytryptamine.

Authors:  Jadwiga Jośko; Jacek Drab; Przemysław Nowak; Ryszard Szkilnik; Eva Körossy; Dariusz Boroń; Halina Brus; Richard M Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2010-09-14       Impact factor: 3.911

7.  Ontogenetic serotoninergic lesioning alters histaminergic activity in rats in adulthood.

Authors:  Jadwiga Jośko; Jacek Drab; Jerzy Jochem; Przemysław Nowak; Ryszard Szkilnik; Eva Korossy-Mruk; Dariusz Boroń; Richard M Kostrzewa; Halina Brus; Ryszard Brus
Journal:  Neurotox Res       Date:  2010-09-14       Impact factor: 3.911

8.  Exploring occupancy of the histamine H3 receptor by pitolisant in humans using PET.

Authors:  Pablo Rusjan; Pamela Sabioni; Patricia Di Ciano; Esmaeil Mansouri; Isabelle Boileau; Alexia Laveillé; Marc Capet; Thierry Duvauchelle; Jean-Charles Schwartz; Philippe Robert; Bernard Le Foll
Journal:  Br J Pharmacol       Date:  2020-05-23       Impact factor: 8.739

9.  Histamine is required for H₃ receptor-mediated alcohol reward inhibition, but not for alcohol consumption or stimulation.

Authors:  J Vanhanen; S Nuutinen; M Lintunen; T Mäki; J Rämö; K Karlstedt; P Panula
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

10.  Histaminergic activity in a rodent model of Parkinson's disease.

Authors:  Przemysław Nowak; Lukasz Noras; Jerzy Jochem; Ryszard Szkilnik; Halina Brus; Eva Körossy; Jacek Drab; Richard M Kostrzewa; Ryszard Brus
Journal:  Neurotox Res       Date:  2009-02-28       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.